Biology of Blood and Marrow Transplantation
Volume 10, Issue 3 , Pages 186-194 , March 2004

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab

  • Irit Avivi

      Affiliations

    • 1Departments of Haematology and Virology, University College Hospital, London, United Kingdom UK
    • ,
  • Suparno Chakrabarti

      Affiliations

    • 2Departments of Haematology and Virology, Birmingham Heartlands Hospital, Birmingham, United Kingdom UK
    • 3Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom UK
    • Corresponding Author InformationCorrespondence and reprint requests: Irit Avivi, MD, Department of Haematology and Bone Marrow Transplantation, Children’s Hospital, Birmingham B4 6NH, UK
    • ,
  • Donald W Milligan

      Affiliations

    • 2Departments of Haematology and Virology, Birmingham Heartlands Hospital, Birmingham, United Kingdom UK
    • ,
  • H Waldmann

      Affiliations

    • 4Sir William Dunn School of Pathology, Oxford, United Kingdom UK
    • ,
  • Geoff Hale

      Affiliations

    • 4Sir William Dunn School of Pathology, Oxford, United Kingdom UK
    • ,
  • Husam Osman

      Affiliations

    • 2Departments of Haematology and Virology, Birmingham Heartlands Hospital, Birmingham, United Kingdom UK
    • ,
  • Katherine N Ward

      Affiliations

    • 1Departments of Haematology and Virology, University College Hospital, London, United Kingdom UK
    • ,
  • Christopher D Fegan

      Affiliations

    • 2Departments of Haematology and Virology, Birmingham Heartlands Hospital, Birmingham, United Kingdom UK
    • ,
  • Kwee Yong

      Affiliations

    • 1Departments of Haematology and Virology, University College Hospital, London, United Kingdom UK
    • ,
  • Anthony H Goldstone

      Affiliations

    • 1Departments of Haematology and Virology, University College Hospital, London, United Kingdom UK
    • ,
  • David C Linch

      Affiliations

    • 1Departments of Haematology and Virology, University College Hospital, London, United Kingdom UK
    • ,
  • Stephen MacKinnon

      Affiliations

    • 1Departments of Haematology and Virology, University College Hospital, London, United Kingdom UK

Received 2 September 2003 ,Accepted 10 November 2003.

References 

  1. Shields AF, Hackman RC, Fife KH, et al.  Adenovirus infections in patients undergoing bone marrow transplantation. N Engl J Med. 1985;312:529–533
  2. Flomenberg P, Babbitt J, Drobyski WR, et al.  Increased incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis. 1994;169:775–781
  3. Blanke C, Clark C, Broun R, et al.  Evolving pathogens in allogeneic bone marrow transplantation (increased fatal adenoviral infections). Am J Med. 1995;99:326–328
  4. Childs R, Sanchez C, Engler H, et al.  High incidence of adeno- and polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine. Bone Marrow Transplant. 1998;22:889–893
  5. La Rosa AM, Champlin RE, Mirza N, et al.  Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis. 2001;32:871–876
  6. Howard DS, Phillips GL, Reece DE, et al.  Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 1999;29:1494–1501
  7. Baldwin A, Kingman H, Darville M, et al.  Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant. 2000;26:1333–1338
  8. Hale GA, Heslop HE, Krance RA, et al.  Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999;23:277–282
  9. Chakrabarti S, Mautner V, Osman H, et al.  Adenovirus infections following allogeneic stem cell transplantation (the incidence and outcome in relation to graft manipulation, immunosuppression and immune recovery). Blood. 2002;100:1619–1627
  10. Chakrabarti S, Mackinnon S, Chopra R, et al.  High incidence of CMV infection after nonmyeloablative stem cell transplantation (potential role of Campath-1H in delaying immune reconstitution). Blood. 2002;99:4357–4363
  11. Chakrabarti S, Avivi I, Mackinnon S, et al.  Respiratory virus infections in transplant recipients after reduced intensity conditioning with Campath-1H (high incidence but low mortality). Br J Haematol. 2002;119:1125–1132
  12. McSweeney PA, Niederwieser D, Shizuru JA, et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies (replacing high-dose cytotoxic therapy with graft-versus-tumor effects). Blood. 2001;97:3390–3400
  13. Slavin S, Nagler A, Naparstek E, et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  14. Giralt S, Thall PF, Khouri I, et al.  Melphalan and purine analog-containing preparative regimens (reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation). Blood. 2001;97:631–637
  15. Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol. 2000;11:6–17
  16. Chakraverty R, Peggs K, Chopra R, et al.  Limiting transplant-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen. Blood. 2001;99:1071–1078
  17. Junghanss C, Boeckh M, Carter RA, et al.  Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002;99:1978–1985
  18. Mohty M, Faucher C, Vey N, et al.  High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant. 2000;26:251–255
  19. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant (correlation with CMV disease and effect of ganciclovir prophylaxis). Blood. 1994;83:1971–1979
  20. Lankester A, Heemskerk B, Vossen T, et al.  Adenovirus infections in pediatric stem cell transplant recipients (feasibility of adoptive cellular immunotherapy). Bone Marrow Transplant. 2003;31(suppl 1):S11
  21. Chakrabarti S, Collingham KE, Fegan C, Milligan DW. Fulminant adenovirus hepatitis following unrelated bone marrow transplantation (failure of intravenous ribavirin therapy). Bone Marrow Transplant. 1999;23:1209–1211
  22. Hammer SM, Inouye RT. Antiviral agents. In:  Richman DD,  Whitley RJ,  Hayden FG editor. Clinical Virology. New York: Churchill-Livingstone; 1997;p. 185–232
  23. Bruno B, Gooley T, Hackman RC, et al.  Adenovirus infection in hematopoietic stem cell transplantation (effect of ganciclovir and impact on survival). Biol Blood Marrow Transplant. 2003;9:341–352
  24. Chakrabarti S, Pillay D, Ratcliffe D, et al.  Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients (risk factors and prognostic significance). J Infect Dis. 2000;181:2055–2058
  25. Prentice HG, Gluckman E, Powles RL, et al.  Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transplant. 1997;19:129–133
  26. Lion T, Baumgartinger R, Watzinger F, et al.  Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood. 2003;102:1114–1120

PII: S1083-8791(03)00475-0

doi: 10.1016/j.bbmt.2003.11.001

Biology of Blood and Marrow Transplantation
Volume 10, Issue 3 , Pages 186-194 , March 2004

Article Tools

* Image Usage & Resolution